Posted by Michael Wonder on 14 Dec 2023
FDA approves eflornithine for adult and paediatric patients with high-risk neuroblastoma
13 December 2023 - Today, the FDA approved eflornithine (Iwilfin) to reduce the risk of relapse in adult and paediatric patients with high risk neuroblastoma who have demonstrated at least a partial response to prior multi-agent, multimodality therapy including anti-GD2 immunotherapy.
This represents the first FDA approval of a therapy intended to reduce the risk of relapse in paediatric patients with high risk neuroblastoma.
